https://www.sec.gov/Archives/edgar/data/1835597/000119312522106884/d235586ds1.htm
Optimistic that RP11 is the real deal that’ll benefit patients, science and PYC/shareholders.
Working on that assumption is mgt believing also their delivery platform is the real deal ushering a new delivery paradigm?
Then maybe it’s buying time to patent up as many leads as possible before more competitors/industry mirror our approach like the above Nasdaq IPO seeking US$100m infusion.
Ann: PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS, page-34
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13987 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 1380 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |